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ABSTRACT Stimulation of fibroblasts with serum growth
factors results in the rapid activation ofa set ofimmediate-early
genes, among them 3CH134. We have purified a bacterially
expressed form of the 3CH134-encoded polypeptide and dem-
onstrated that it has intrinsic protein-tyrosine-phosphatase
(PTPase; protein-tyrosine-phosphate phosphohydrolase, EC
3.1.3.48) activity in vitro. This activity is optimal at pH 7.5, is
sensitive to vanadate and cysteinyl modifying agents, and is
insensitive to a panel of serine/threonine phosphatase inhibi-
tors. Purified 3CH134 protein displays a high degree of selec-
tivity among the tyrosine-phosphorylated polypeptide sub-
strates tested. Under our assay conditions, the rates of dephos-
phorylation are in the order EDNDYINASL peptide < myelin
basic protein < reduced, carboxyamidomethylated, and ma-
leylated lysozyme (RCML) < p42m%*. There is a 200-fold
range in rates for these substrates, with p42maPac dephospho-
rylated 15-fold more rapidly than RCML. Although 3CH134 is
most closely related to the tyrosine/serine dual-speciffcity
phosphatase VH1, we failed to detect any 3CH134-directed
activity on casein or RCML phosphorylated on ser-
ine/threonine residues by cAMP-dependent protein kinase.
Since 3CH134 expression is controlled transcriptionally and
posttranscriptionally, it may represent a class of PTPases
whose activity is regulated at the level of protein synthesis and
degradation.
Serum growth factors stimulate cell proliferation through
interactions with their specific cell-surface receptors, acti-
vating the intrinsic receptor protein-tyrosine kinases (PTKs;
ATP: protein-tyrosine O-phosphotransferase, EC 2.7.1.112).
This leads to signal transduction events that include revers-
ible phosphorylation of a number of cellular substrates on
tyrosyl residues. Some of these signals are transmitted to the
nucleus, where the activation of a set of immediate-early
genes occurs. These immediate-early genes encode a diverse
array of regulatory proteins including transcription factors
and cytokines (1-3). Their expression has been hypothesized
to mediate the biological effects of the stimulatory growth
factor.
An important feature of these phosphorylation events is
their reversibility. The actions of PTKs in conjunction with
the activity of a family of protein-tyrosine-phosphatases
(PTPases; protein-tyrosine-phosphate phosphohydrolase,
EC 3.1.3.48) control the phosphorylation state of tyrosyl
residues in signaling proteins. The PTPases include trans-
membrane, receptor-like, and cytoplasmic enzymes defined
by a unique sequence motif, (I/V)HCXAGXXR(S/T)G (4).
We have noted that this motif, which contains a cysteinyl
residue essential for activity, is present in the predicted
sequence of the protein product encoded by the immediate-
early gene 3CH134 (5).
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3CH134 is activated rapidly and transiently in quiescent
fibroblasts treated with serum growth factors (6). 3CH134 is
also expressed during liver regeneration soon after partial
hepatectomy (7), further suggesting a link between its ex-
pression and the control of cell growth. Its transcription in
fibroblasts is detected within minutes of growth factor addi-
tion, reached a peak level by 10-20 min, and is repressed after
1 h (8). The 3CH134 mRNA has a very- short half-life and
accumulates for only 1-2 h during the Go/Gl transition.
Likewise, the 3CH134 protein is transiently synthesized and
has a half-life of 40 min (5).
In this communication, we show directly that the 3CH134-
encoded protein dephosphorylates phosphotyrosyl protein
substrates in vitro, including the p42 mitogen-activated pro-
tein kinase (MAP kinase) (p42maPk). 3CH134 may thus rep-
resent a class of tyrosine phosphatases whose genes are
mitogen activated and whose activities may regulate the
signal transduction cascade stemming from the receptor
tyrosine kinases.
MATERIALS AND METHODS
Substrate Preparation. Reduced, carboxyamidomethy-
lated, and maleylated lysozyme (RCML) and myelin basic
protein were prepared as described (9, 10) and phosphory-
lated on tyrosyl residues using a cytoplasmic fragment of the
(3 subunit of the insulin receptor kinase (BIRK; ref. 11)
produced in recombinant baculovirus-infected SF9 cells. The
phosphorylation reaction mixture, consisting of 50 mM
Tris HCl, pH 7.5/4 mM MnCl2/10 mM MgSO4/2 mM 1,4-
dithiothreitol (DTT)/2 mM ATP/0.1 mM Na3VO4/2 mg of
RCML per ml/l mCi of [y-32P]ATP per ml (1 Ci = 37 GBq),
was incubated for 6 h at 30°C. The reaction was then stopped
with the addition of trichloroacetic acid (TCA) to 10%o and
incubated on ice for 20 min. The precipitated protein was
washed three times with ice-cold TCA, resuspended in 2 M
Tris base on ice, and dialyzed against several changes of 50
mM imidazole (pH 7.2). A phosphotyrosyl synthetic peptide
derived from the site of phosphorylation by v-Abl of PTP1B
(EDNDYINASL) was phosphorylated under similar condi-
tions and purified by reverse-phase HPLC. Autophosphory-
lated BIRK was prepared as described (12). Serine phos-
phorylated substrates were prepared with the catalytic sub-
unit of protein kinase A in a reaction mixture consisting of 50
mM Tris-HCl, pH 7.2/10 mM MgCl2/2 mM ATP/2 mM
DTT/1 mCi of [t-32P]ATP per ml/2 mg ofRCML per ml or
10 mg of casein per ml. Phosphorylated substrates were
purified as described above and stored at 4°C.
Abbreviations: PTK, protein-tyrosine kinase; PTPase, protein-
tyrosine-phosphatase; RCML, reduced, carboxyamidomethylated,
and maleylated lysozyme; MAP kinase, mitogen-activated protein
kinase; BIRK, (3 subunit of insulin receptor kinase; DTT, 1,4-
dithiothreitol; BSA, bovine serum albumin.
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Preparation of a Substrate Affinity Column. Thiophospho-
tyrosyl RCML (10) was prepared by incubation ofRCML with
the BIRK enzyme in the reaction mixture described above
except that ATP was replaced by 1 mM adenosine 5'-[y-
thio]triphosphate (ATP[yS]) and 250 ,uCi of ATP[y-35S]. This
reaction mixture was incubated for 12 h at 30°C and terminated
by addition ofTCA; then the thiophosphoprotein was washed
and solubiized as described above. Thiophosphotyrosyl
RCML (0.7 mol of thiophosphate per mol of protein) was
dialyzed against 0.1 M NaHCO3/0.5 M NaCl and coupled to
CNBr-activated Sepharose-4B beads (Pharmacia); 1.5 mg of
RCML protein was coupled per ml of CNBr Sepharose.
Protein Purification. A DNA fragment containing nucleo-
tides 138-1930 of the 3CH134 cDNA (5) was cloned into the
T7 RNA polymerase-based expression vector pET3b (13) and
transformed into Escherichia coli strain BL21 DE3. This
construct expresses a recombinant 3CH134 protein that is
full-length with an N-terminal extension of 16 amino acids
(MASMTGGQQMGRRDPA). An overnight culture of bac-
teria was diluted 1:50 into LB medium and grown at 30°C until
A600 = 0.8. Synthesis of3CH134 protein was induced with 0.8
mM isopropyl P3-D-thioglucopyranoside as the cells contin-
ued to grow at room temperature for an additional 4 h. All
subsequent steps were performed at 4°C. Cells were har-
vested by centrifugation at 3000 x g and resuspended in lysis
buffer consisting of 20mM Hepes, pH 7.5/10mM NaCl/10%
(vol/vol) glycerol/5 mM EDTA/5 mM DTT/5 ,ug of aproti-
nin per ml/5 ,g ofleupeptin per ml/1 mM benzamidine/2 ,M
pepstatin/0.1 mM phenylmethylsulfonyl fluoride (PMSF).
Cells were lysed by two passes through a French press. Cell
debris was removed by centrifugation at 10,000 x g for 20 min
and the supernatant containing the soluble 3CH134 protein
was assayed for PTPase activity.
To purify the recombinant 3CH134 protein, the lysate was
adsorbed batchwise to S-Sepharose fast flow ion-exchange
resin (Pharmacia), which had been equilibrated with buffer A
(10 mM Hepes, pH 7.5/0.1% 2-mercaptoethanol/1 mM
EDTA/1 mM benzamidine/0.2 mM PMSF). The phospha-
tase activity was eluted with buffer A containing 500 mM
NaCl, and the eluate was dialyzed against buffer A. The
dialysate was applied to a Mono S HR 5/5 column (Pharma-
cia), which had been equilibrated with buffer B (10 mM
Hepes, pH 7.5/1 mM EDTA/2 mM DTT/1 mM benzami-
dine/0.2 mM PMSF). Proteins were eluted from the column
at 1 ml/min with a linear gradient of 0-1 M NaCl in buffer B.
Activity was recovered in the fractions containing 350-450
mM NaCl, pooled, diluted 1:10 with buffer A, and loaded
onto the 1.5-ml thiophosphotyrosyl RCML affinity column.
The column was washed with 15 ml of buffer A and then with
15 ml of buffer A containing 50 mM NaCl. 3CH134 protein
was eluted with incremental washes of 50 mM NaCl up to 300
mM in buffer A. Active fractions in 100-150 mM NaCl were
pooled, mixed with 0.2 mg of bovine serum albumin (BSA)
per ml to stabilize enzyme activity, and frozen in 50%o
glycerol at -70°C.
Phosphatase Activity Assay. A standard assay of phospha-
tase activity contained 50 mM Hepes (pH 7.5), 1 mg of BSA
per ml, 2 mM DTT, 1 ,uM tyrosine-phosphorylated RCML
[Tyr(P)-RCML], and purified 3CH134 protein in a final
reaction vol of 60 ,ul. After incubation for 10 min at 30°C,
reactions were stopped by using an activated charcoal mix-
ture as described (12).
Immunoblotting. Proteins were separated by SDS/PAGE,
transferred to nitrocellulose (14), and detected by immuno-
blotting. 3CH134 was detected with affinity-purified anti-
3CH134 antibody (5), MAP kinase was detected with poly-
clonal antibody R2 (UBI, Lake Placid, NY), while phospho-
tyrosine was detected with the monoclonal antibody 4G10
(UBI). All antibodies were diluted in TTBS (20 mM Tris/
0.05% Tween 20/0.5 M NaCl) containing 5% nonfat dry milk.
Blots were washed three times in TTBS and then incubated
with the appropriate secondary antibodies. After washing,
immunoreactive proteins were detected through the use of
enhanced chemiluminescence (ECL; Amersham).
Dephosphorylation of MAP Kinase. Bacterially expressed
mouse p42maPk, phosphorylated primarily at tyrosine-185
using purified MAP kinase kinase (15), was generously pro-
vided by Timothy Haystead (University of Virginia). De-
phosphorylation was carried out in 40mM Hepes, pH 7.5/0.1
mg of BSA per ml/2 mM DTT/1 ,uM phosphorylated p42maPk
using either purified 3CH134 or PTP1B purified from human
placenta (10). The mixtures were incubated at 30°C for
various times, stopped by addition of 2x SDS sample buffer
(14), resolved by SDS/10% PAGE, and immunoblotted. The
reactive protein bands detected by ECL were quantitated
with the computing densitometer Image Quant (Molecular
Dynamics).
RESULTS
The Immediate-Early Gene 3CH134 Encodes a PTPase. To
test whether the 3CH134-encoded protein, which contains
the sequence motif (I/V)HCXAGXXR(S/T)G, is indeed a
tyrosine phosphatase, we produced the 3CH134 protein by
using a bacterial expression vector. PTPase activity, as
judged by dephosphorylation of Tyr(P)-RCML, was readily
detected in lysates from cells transformed with the 3CH134
expression construct but not in lysates from cells transformed
with the parental vector (data not shown). To demonstrate
that the 3CH134 protein contains an intrinsic PTPase activity,
we purified and characterized the recombinant 3CH134 poly-
peptide. Lysates from cells expressing 3CH134 were passed
sequentially over an S-Sepharose fast flow column, a Mono
S HR 5/5 ion-exchange column, and a thiophosphotyrosyl-
RCML affinity column (Table 1). Each step ofthe purification
was monitored by assay of PTPase activity and immunoblot-
ting with affinity-purified anti-3CH134 antibodies (5).
Despite the use of a protease-deficient strain of E. coli and
the inclusion of a broad spectrum of protease inhibitors, the
bacterially expressed 3CH134 protein is highly labile. In
bacterial cell lysates, the major antigenic 3CH134 species
include a full-length form, migrating with the expected mo-
bility of 40 kDa, and a truncated 35-kDa protein. After
ion-exchange and affinity chromatography a more exten-
sively truncated 3CH134 polypeptide, running as a doublet at
23 kDa, was enriched >500-fold as an active PTPase to near
homogeneity (Fig. 1). Activity correlated with the appear-
ance of the immunoreactive proteins during purification
(Table 1). Dephosphorylation was linear with time and en-
zyme concentration. In addition to Tyr(P)-RCML, 3CH134
Table 1. Purification of 3CH134
Protein Total Total
Vol, concentration, protein, activity, Specific activity, Yield, Purification,
ml mg/ml mg pmol/min pmol min-l.mg-1 % -fold
Crude extract 40 14.3 572 709 1.2 100 1
S-Sepharose 54 0.38 20.5 2000 97.6 282 81
Mono S 2 0.30 0.6 229 381 32 317
RCML Sepharose 2.5 0.06 0.15 104 693 15 577
Biochemistry: Charles et al.
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FIG. 1. Purification of recombinant 3CH134 protein expressed in
bacteria. (A) Coomassie blue-stained SDS/12% PAGE analysis of
proteins after each stage of purification. Lanes: 1, 2.5 ,g of total
lysate; 2, 2.5 ,Lg of S-Sepharose eluate; 3, 0.5 .g of Mono S eluate;
4, 0.5 ug of thiophosphotyrosyl RCML Sepharose eluate. Mobilities
of molecular mass markers are indicated (kDa). (B) Immunoblot of
a gel similar to that in A (except lanes 3 and 4 contain -0.25 jug of
protein) probed with affinity-purified anti-3CH134 antibodies and
peroxidase-coupled donkey anti-rabbit IgG (Amersham) detected
with enhanced chemiluminescence.
also dephosphorylated Tyr(P)-myelin basic protein and the
EDNDYINASL peptide, albeit with lower efficiency (data
not shown).
Characterization of 3CH134 PTPase Activity. Assay of
purified 3CH134 across the pH range 6.0-9.0 showed that the
enzyme is most active at pH 7.5, with little activity at pH 6.0
or 9.0 (Fig. 2A). The PTPase activity was sensitive to the
classic PTPase inhibitor vanadate, with >90% inhibition at 1
mM (Fig. 2B). However, it was not sensitive to the alkaline
phosphatase inhibitor tetramisole, the acid phosphatase in-
hibitor tartrate, or inhibitors of phosphatases 1 and 2A,
okadaic acid and microcystin-LR. The PTPase activity of
3CH134 required the presence of a reducing agent and was
abrogated by cysteinyl-modifying agents such as iodoacetic
acid or N-ethylmaleimide (Fig. 2B).
3CH134 Does Not Dephosphorylate Phosphoseryl/Threonyl
Substrates. Tyr(P)-RCML is readily dephosphorylated by
3CH134. Therefore, in order to examine the potential dual
specificity of this enzyme, we tested whether it could de-
phosphorylate RCML phosphorylated by cAMP-dependent
protein kinase. This has been used as a substrate for other
phosphatases (16). Under assay conditions in which the
phosphotyrosyl protein was dephosphorylated, phospho-
serine/threonine RCML was not susceptible to 3CH134 (Fig.
3). Similarly, there was no detectable dephosphorylation of
the more commonly used substrate phosphoseryl casein. In
both cases, no activity was observed under conditions vary-
ing from pH 6.0 to pH 9.0 (data not shown).
Dephosphorylation of MAP Kinase by 3CH134. Since the
synthesis of 3CH134 occurs soon after growth factor addi-
tion, one might expect its physiological substrates to be
proteins phosphorylated on tyrosyl residues shortly after
mitogenic stimulation. The MAP kinases, which are signal-
transducing enzymes activated by tyrosine phosphorylation
(17, 18), are candidate substrates. We thus examined the
ability of 3CH134 to dephosphorylate recombinant p42maPk,
which was phosphorylated on tyrosyl residues in vitro using
MAP kinase kinase (15). The reaction products were ana-
lyzed by parallel immunoblots with antibodies specific for
MAP kinase and a monoclonal antibody specific for phos-
photyrosine (Fig. 4). Dephosphorylation of p42maPk was
observed accompanied by a shift in its electrophoretic mo-
bility to a faster-migrating species and by the disappearance
of the immunoreactive protein recognized by the anti-
phophotyrosine antibody.
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FIG. 2. Characterization of 3CH134 PTPase activity. (A) pH
optimum. Purified 3CH134 was assayed with 2.5 ,uM phosphotyrosyl
RCML. Reactions were assayed under standard conditions, buffered
at pH 6 or 6.5 with 40 mM Mes; at pH 7.0 or 7.5 with 40 mM Hepes;
and at pH 8.0, 8.5, or 9.0 with 40 mM Tris. (B) Effects ofphosphatase
inhibitors. Activity of purified 3CH134 on 2.5 ,uM Tyr(P)-RCML was
measured under standard assay conditions in 40mM Hepes (pH 7.5).
Activity was measured in the presence of 10 mM iodoacetic acid, 10
mM N-ethylmaleimide, 1 mM sodium orthovanadate, 1 AM okadaic
acid, 0.1 ,uM microcystin-LR, 1 mM tetramisole, or 5 mM tartrate.
Dephosphorylation is presented as the percentage of that observed
in the absence of inhibitors (standard).
The 3CH134 phosphatase appears to display a high degree
of substrate selectivity in vitro. p42maPk was dephosphorylated
with highest efficiency, some 15-fold more rapidly thanRCML
(Fig. SA), which was in turn dephosphorylated 3- and 15-fold
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FIG. 3. Time course of dephosphorylation of RCML. Purified
3CH134 was incubated under standard assay conditions with either
2.5 ,uM phosphotyrosyl RCML (o) or 2.5 A&M phosphoseryl/threonyl
RCML (v) for the indicated times in assay buffer containing 40 mM
Hepes (pH 7.5), 1 mg of BSA per ml, and 2 mM DTT.
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FIG. 4. Dephosphorylation of p42maPk by 3CH134. 3CH134 or
PTP1B was incubated with 1 /,M p42maPk phosphorylated primarily
on Tyr-185 in 40 mM Hepes, pH 7.5/0.1 mg ofBSA per ml and 2 mM
DTT. Since PTP1B activity is enhanced in 1 mM EDTA, it was
included in the PTP1B assay buffer. Equivalent units of activity of
3CH134 and PTP1B on Tyr(P)-RCML (1 ,uM) were used in each
reaction. Incubations were allowed to proceed for the indicated times
and were terminated by addition of 2x sample buffer. Reaction
products were analyzed in parallel immunoblots with anti-MAP
kinase (anti-MAPK) antibodies or anti-phosphotyrosine (anti-PTyr)
antibody as indicated and were detected by enhanced chemilumi-
nescence.
more rapidly than myelin basic protein and the peptide EDN-
DYINASL, respectively (data not shown). In contrast,
PTP1B, which dephosphorylates many in vitro substrates
efficiently (19), dephosphorylated these artificial substrates
with similar efficiency but dephosphorylated p42maPk at a very
slow rate (Fig. 4). The possibility that 3CH134 may act on
growth factor receptor PTKs was tested with BIRK, the
cytoplasmic domain of the insulin receptor that was autophos-
phorylated on tyrosyl residues in vitro. Under conditions in
which 3CH134 readily dephosphorylated p42maPk, there was
no apparent dephosphorylation of BIRK (Fig. 5B).
DISCUSSION
The characterization of growth factor-inducible immediate-
early genes has led to the identification of regulatory mole-
cules, including transcription factors and cytokines (1). We
show here that the immediate-early gene 3CH134 (5) encodes
a PTPase. 3CH134 is thus an example of a PTPase whose
gene is transcriptionally activated by serum growth factors.
The PTPase family of enzymes includes a structurally
diverse array of proteins consisting of transmembrane, re-
ceptor-like, and cytoplasmic forms (4). Despite this structural
diversity, each member of the family is characterized by the
presence of a segment of 1240 residues that presumably
represents the catalytic domain. The signature motif (I/
V)HCXAGXXR(S/T)G, located near the C terminus of this
domain, contains the catalytically essential cysteine residue.
The 3CH134 phosphatase is most closely related to the
vaccinia virus protein VH1, whose structural similarity to
previously defined PTPases was restricted to -30 residues
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FIG. 5. Substrate specificity of purified 3CH134. (A) Dephos-
phorylation of p42maPk (0) was quantitated by densitometer tracing
of the appearance of the dephosphorylated p42mIPk species with
faster electrophoretic mobility on the exposed x-ray film (see Fig. 4).
Dephosphorylation of labeled Tyr(P)-RCML (o) was quantitated by
scintillation counting of released free 32Pi. Both substrates were
assayed at 1 ,uM Tyr(P) concentration for the indicated times. (B)
Comparison of activities of 3CH134 on phosphotyrosyl p42maPk and
phosphotyrosyl BIRK. Each substrate was assayed at 0.5 ,uM
phosphotyrosyl protein concentration for the indicated times (min-
utes) and analyzed by SDS/PAGE. Dephosphorylation of p42MIPk
(Upper) was monitored by immunoblotting with anti-phosphoty-
rosine antibody as described in Fig. 4. Dephosphorylation of 32p-
labeled BIRK (Lower) was examined by autoradiography.
surrounding the consensus motif (20). It now appears that
VH1 can be regarded as the prototype of a broad subfamily
of PTPases that also includes CDC14 from Saccharomyces
cerevisiae (21); an open reading frame from Autographa
californica (16); cdc25, the PTPase that dephosphorylates
and activates p34cdc2 (22, 23); YVH1 from S. cerevisiae (24);
and VHR from human lung fibroblasts (25). An alignment of
some of these protein sequences is presented in Fig. 6.
While this manuscript was being prepared, the human
homolog of 3CH134, named CL100, which is activated by
PVE ILSFLYLQSAYHASRKDMLDALG ITAL1NV.SANCPNHFEGHY.S' VEQNHKA SWQN'F I I
LGGIYLGGIRPIIDHRPLGAEFNITHILSVIKFQVIPEYLIRKGYTLKNMIDTDDVTiVLQY#0TNR Q*
MTRVTNNVYLJN-YKNAMDAPSSEVKFKYVLNLTMDKYTLPNSNINIH LVbDTTT"T KYfDDVTAFLSKCD
VG NASVAQD I P KLQK LG I THVVLNAAEG R S FMHVNTNANFYKDSGITYLGKANDTQEFNLAA4ERMAKQA*
KEM.-FEDTNkKLTLISEDIKSYYTVRQLEIENLTTQETRE ILHFHYTTWPDFGVPESPAS FLNLFKVRESGS LS
TV.DGKHQDLKYISP.ETMVALLTGKFSNI VEKFVIVDQRYPYE:YEGGHIKNAVNLPLERDAETFLLQRPIMPCSLD
3 C H 1 3 4DAGGTNVTI0gRrNRVK:LDEAFEFVKQRRS !IS,8.F.SfA G.QLLG F
-SQV LAPHCSAE
YVH1 P -RA IF LSRIVTFIAV."VY RYG LSLSMAMHAVKRKKPSVEPNEN HELHL'FKMGGDFVDFN
VH1 QR NE PyLNL VNR.$GAM I LSKNKES LPMLYFLYVYHSMRDLRGAFVENPSFKRQIIEKYVIDKN
VHR QKNGRL) fEGYSLRAPTLVILLMNMRQKMDVKSALSIVRQNREIG-PN0GFLAQLCQLNDLAKEGKLKP
PTP1B P EHPlV IGRSSG:GFTCLADTCLLLMDKRRKDPSSVDIKKVLLEMRK'FRMGLIQTADQLRFSYLAVI EG
cdc25M KRHIILIFCEFSSERGPRMCRFIRERRDRAANDYPSLYYPEMYILKGGYKEFFPQHPNFCEPQDYRtMNHEA
FIG. 6. Comparison of 3CH134 to other PTPase protein sequences. Shown are the amino acid sequences from 3CH134 (aa 174-320; ref. 5),
YVH1 (aa 17-179; ref. 24), VH1 (aa 27 to end; ref. 20), VHR (aa 39 to end; ref. 25), human PTP1B (aa 131-279; ref. 26), and mouse cdc25 (aa
400-545; ref. 22). Identities with 3CH134 are shaded. aa 89-106 in YVH1 and aa 113 and 114 in VHR were omitted to maximize alignment and
are represented by asterisks in the aligned sequences.
Biochemistry: Charles et al.
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oxidative stress and heat shock, was demonstrated to hydro-
lyze the phosphate ester pNPP in vitro (27). However, under
various assay conditions, several enzymes other than phos-
phatases can hydrolyze pNPP (28). Here we demonstrate
directly that 3CH134 possesses intrinsic PTPase activity
toward several phosphotyrosyl proteins in vitro. Moreover,
it displays a high degree of substrate selectivity, with a
preference for p42maPk among the substrates tested.
The specific activity of the 3CH134 PTPase is low when
standard artificial substrates are used in vitro. A number of
factors may contribute to this. (i) The 23-kDa form of3CH134
may exhibit altered activity. However, the activity of the
full-length form of 3CH134 in bacterial lysates toward
RCML, myelin basic protein, and EDNDYINASL peptide
was similar to the purified truncated form. Nonetheless, the
possibility that the truncated 3CH134 may show differences
in specific activity and/or substrate selectivity from the
full-length form cannot be ruled out. Furthermore, as is a
common problem in bacterial expression systems, a signifi-
cant proportion of the protein may be denatured. (ii) A
catalytically significant posttranslational modification may
be absent due to the use of bacterial expression systems to
produce recombinant protein. In this regard, it is interesting
to note that the activity of cdc25 is increased in M phase,
concomitant with hyperphosphorylation of the protein (29).
(iii) The contribution of an associated protein may also be
important for activity, as has been proposed for cyclin B in
the activation of cdc25 (30). Thus, although several of the
previously characterized PTPases, including PTP1B, display
broad substrate specificity in vitro, many of the standard
model substrates may be inappropriate for 3CH134.
3CH134 is most closely related to YVH1 (24), VHR (25),
and VH1 (ref. 20; Fig. 6). Levels of both 3CH134 and YVH1
are controlled transcriptionally, the latter being induced by
nitrogen starvation (24). Although VH1 and VHR possess
dual specificity for dephosphorylation of phosphoseryl and
phosphotyrosyl residues in proteins, neither 3CH134 nor
YVH1 dephosphorylates the selection of phosphoseryl/
threonyl substrates tested under conditions in which they
exhibit PTPase activity. Nevertheless, given the similarity to
the dual specificity PTPases VH1 and VHR, it is possible that
3CH134 may demonstrate phosphatase activity against phos-
phoseryl or phosphothreonyl residues in addition to phos-
photyrosyl residues under physiological conditions with an
appropriate substrate.
The identity of physiologically relevant substrates for
3CH134 remains to be established. In light of the rapid and
transient appearance of 3CH134 mRNA and protein after
stimulation ofquiescent cells with serum or growth factors (5,
6, 8), a role in the regulation of early steps in signal trans-
duction from growth factor receptor PTKs is possible. At
least two sites of action would be consistent with such a role:
the receptor PTKs or the downstream serine/threonine ki-
nases that are themselves regulated by reversible tyrosine
phosphorylation. As an example of the former category, we
assayed Tyr(P)-BIRK, the recombinant catalytic domain of
the insulin receptor, which has been used as a substrate for
PITPases in vitro (12). No significant dephosphorylation by
purified 3CH134 was detected. Candidate substrates in the
latter category include the MAP kinases (18). A diverse array
of hormones and growth factors elicit a rapid and transient
activation of MAP kinases as an essential step in their
signaling pathways. Maximal activation of MAP kinases
requires phosphorylation of both a tyrosyl and a threonyl
residue in the protein; dephosphorylation of either severely
attenuates activity (31). Here we demonstrate that 3CH134
dephosphorylates Tyr(P)-p42maPk in vitro 15-fold more rap-idly than Tyr(P)-RCML and 200-fold more rapidly than the
phosphorylated synthetic peptide EDNDYINASL. The pos-
sibility that, among other potential physiological substrates,
3CH134 acts on members of the MAP kinase family in vivo
clearly merits further attention.
We are very grateful to Tim Haystead of the University of Virginia
for providing us with recombinant p42mIPk substrate. Recombinant
baculovirus expressing BIRK was provided by Melanie Cobb (Uni-
versity ofTexas Southwestern Medical Center, Dallas) and prepared
by Andrew Flint. We also thank Bob DelVecchio and Andrew Flint
for helpful discussions and Carol Marcincuk for typing the manu-
script. This work was supported by National Institutes of Health
Grants CA53840 (N.K.T.) and CA46565 (L.F.L.). N.K.T. acknowl-
edges support from the Hansen Memorial Foundation. C.H.C. was
a predoctoral fellow of the National Science Foundation, H.S. is a
recipient of a Damon Runyan-Walter Winchell Cancer Research
Fund fellowship, N.K.T. is a Pew Scholar in the Biomedical Sci-
ences, and L.F.L. is an Established Investigator of the American
Heart Association.
1. Lau, L. F. & Nathans, D. (1991) in Molecular Aspects of Cellular
Regulation, Vol. 6. Hormonal Regulation of Transcription, eds.
Cohen, P. & Foulkes, J. G. (Elsevier, Amsterdam), pp. 257-293.
2. Williams, G. T., Abler, A. S. & Lau, L. F. (1992) in Molecular and
Cellular Approaches to the Control of Proliferation and Differen-
tiation, eds. Stein, G. S. & Lian, J. B. (Academic, Orlando, FL),
pp. 115-162.
3. Herschman, H. R. (1991) Annu. Rev. Biochem. 60, 281-319.
4. Charbonneau, H. & Tonks, N. K. (1992) Annu. Rev. Cell Biol. 8,
463-493.
5. Charles, C. H., Abler, A. S. & Lau, L. F. (1992) Oncogene 7,
187-190.
6. Lau, L. F. & Nathans, D. (1985) EMBO J. 4, 3145-3151.
7. Nathans, D., Lau, L. F., Christy, B., Hartzell, S., Nakabeppu, Y.
& Ryder, K. (1988) Cold Spring Harbor Symp. Quant. Biol. 53,
893-900.
8. Lau, L. F. & Nathans, D. (1987) Proc. Natl. Acad. Sci. USA 84,
1182-1186.
9. Crestfield, A. M., Moore, S. & Stein, W. H. (1963) J. Biol. Chem.
238, 622-627.
10. Tonks, N. K., Diltz, C. D. & Fischer, E. H. (1991) Methods En-
zymol. 201, 427-442.
11. Villalba, M., Wente, S. R., Russell, D. S., Ahn, J., Reichelderfer,
C. F. & Rosen, 0. M. (1989) Proc. Natl. Acad. Sci. USA 86,
7848-7852.
12. Yang, Q., Co, D., Sommercorn, J. & Tonks, N. K. (1993) J. Biol.
Chem. 268, 6622-6628.
13. Studier, F. W., Rosenberg, A. H., Dunn, J. J. & Dubendorff, J. W.
(1990) Methods Enzymol. 185, 60-89.
14. Harlow, E. & Lane, D. (1988) Antibodies: A Laboratory Manual
(Cold Spring Harbor Lab., Plainview, NY).
15. Haystead, T. A. J., Dent, P., Wu, J., Haystead, C. M. M. &
Sturgill, T. W. (1992) FEBS Lett. 306, 17-22.
16. Sheng, Z. & Charbonneau, H. (1993)J. Biol. Chem. 268, 4728-4733.
17. Thomas, G. (1992) Cell 68, 3-6.
18. Blenis, J. (1991) Cancer Cells 3, 445-449.
19. Tonks, N. K., Diltz, C. D. & Fischer, E. H. (1988) J. Biol. Chem.
263, 6731-6737.
20. Guan, K., Broyles, S. S. & Dixon, J. E. (1991) Nature (London)
350, 359-362.
21. Wan, J., Xu, H. & Grunstein, M. (1992) J. Biol. Chem. 267,
11274-11280.
22. Strausfeld, U., Labbe, J. C., Fesquet, D., Cavadore, J. C., Picard,
A., Sadhu, K., Russel, P. & Dor6e, M. (1991) Nature (London) 351,
242-245.
23. Lee, M. S., Ogg, S., Xu, M., Parker, L. L., Donoghue, D. J.,
Maller, J. L. & Piwnica-Worms, H. (1992) Mol. Biol. Cell 3,73-84.
24. Guan, K., Hakes, D. J., Wang, Y., Park, H.-D., Cooper, T. G. &
Dixon, J. E. (1992) Proc. Natl. Acad. Sci. USA 89, 12175-12179.
25. Ishibashi, T., Bottaro, D. P., Chan, A., Miki, T. & Aaronson, S. A.
(1992) Proc. Natl. Acad. Sci. USA 89, 12170-12174.
26. Chernoff, J., Schievella, A. R., Jost, C. A., Erikson, R. L. & Neel,
B. G. (1990) Proc. Natl. Acad. Sci. USA 87, 2735-2739.
27. Keyse, S. M. & Emslie, E. A. (1992) Nature (London) 359, 644-
647.
28. Sparks, J. W. & Brautigan, D. L. (1986) Int. J. Biochem. 18,
497-504.
29. Kumagai, A. & Dunphy, W. G. (1992) Cell 70, 139-151.
30. Galaktionov, K. & Beach, D. (1991) Cell 67, 1181-1194.
31. Anderson, N. G., Maller, J. L., Tonks, N. K. & Sturgill, T. W.(1990) Nature (London) 343, 651-653.
52% Biochemistry: Charles et al.
